Safety of meningococcal group B vaccination in hospitalised premature infants
<h4>Objectives</h4> <p>To assess the risk of significant adverse events in premature infants receiving the novel 4-component group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age.</p> <h4>Participants, design and setting</h4>...
| Автори: | , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
BMJ Publishing Group
2018
|